Membrane Oxygenators Market by Product Type (Cardiopulmonary Bypass Oxygenators, Extracorporeal Life Support Oxygenators, Integrated Oxygenator-Heat Exchangers), Material (Polymethylpentene, Polypropylene, Polysulfone), Flow Configuration, Temperature, Ap
Description
The Membrane Oxygenators Market was valued at USD 659.81 million in 2024 and is projected to grow to USD 704.16 million in 2025, with a CAGR of 6.77%, reaching USD 1,114.34 million by 2032.
A concise overview of membrane oxygenator relevance across clinical, research and perfusion applications emphasizing technological and clinical drivers
Membrane oxygenators sit at the intersection of critical-care innovation and biomedical engineering, serving as indispensable components in extracorporeal life support and perfusion systems. Over the past decade, clinicians and researchers have relied on advances in membrane design and polymer science to sustain complex cardiopulmonary procedures and to enable prolonged extracorporeal support in acute respiratory and cardiac failure. The technology’s utility spans controlled laboratory environments and high-acuity clinical settings, where device performance directly influences patient outcomes.
This introduction frames the current landscape by emphasizing converging drivers: evolving clinical demand patterns, material and manufacturing breakthroughs, and heightened regulatory scrutiny around biocompatibility and sterility. The narrative draws attention to distinctions in form factors and configurations that influence clinical adoption, and it underscores the interplay between device architecture and procedural applications. By situating membrane oxygenators within wider healthcare delivery trends-such as increasing emphasis on minimally invasive procedures and expanding use of extracorporeal support-this section sets the context for deeper analysis of market dynamics, technological inflection points, and strategic considerations for manufacturers and healthcare purchasers alike.
How material breakthroughs clinical practice evolution and supply resiliency initiatives are reshaping product design adoption and competitive positioning
The landscape for membrane oxygenators is undergoing a sequence of transformative shifts driven by material innovation, clinical practice changes, and supply chain realignment. Recent progress in polymer science, particularly the broader adoption of advanced hollow fiber membranes and next-generation polymethylpentene materials, has improved gas exchange efficiency and reduced plasma leakage, prompting device redesigns and reconsideration of perfusion protocols. Concurrently, clinical pathways have shifted toward more frequent and earlier deployment of extracorporeal support in severe respiratory failure, which in turn has elevated expectations for device endurance, ease of priming, and integration with monitoring platforms.
Manufacturers are responding by modularizing product families and prioritizing single-use disposables that balance infection control with operational efficiency. At the same time, intensified regulatory attention on biocompatibility, sterilization validation, and real-world performance data is reshaping R&D priorities and clinical evidence generation. Digital tooling and simulation are being applied to accelerate development cycles and to optimize flow configurations for specific surgical and extracorporeal use cases. As stakeholders adapt, strategic emphasis is shifting from incremental improvements to systemic rethinking of supply resiliency, clinical training, and lifecycle cost management, creating new opportunities for differentiated product positioning and collaborative clinical research.
Strategic consequences of 2025 United States tariff actions on sourcing manufacturing partnerships pricing models and procurement resilience
United States tariff measures announced in 2025 have introduced a new layer of strategic complexity for manufacturers and purchasers of membrane oxygenators, prompting operational adjustments across sourcing, pricing, and distribution networks. The tariffs have encouraged organizations to re-evaluate global procurement footprints and to accelerate consideration of nearshoring or local manufacturing partnerships as a means to insulate operations from trade-related cost volatility. Procurement teams have increasingly prioritized supplier diversification and long-term contracts with clauses that mitigate exposure to tariff fluctuations, while product teams are reassessing the total cost implications of material choices and component sourcing.
Regulatory and reimbursement environments have also been indirectly affected, as hospitals and purchasing coalitions seek transparent cost justifications for capital and disposable device selections. In response, suppliers have intensified efforts to demonstrate value through clinical evidence, reduced operating times, and lower complication rates rather than relying solely on purchase price. The tariffs have further incentivized innovation in material efficiency and manufacturing automation to offset added customs-related expenses. Ultimately, organizations that proactively adapt pricing models, secure resilient supplier arrangements, and provide clear clinical and economic value narratives are positioned to navigate the tariff environment with less disruption to patient care and supply continuity.
Deep segmentation-driven insights revealing how type application end-user material flow configuration and temperature considerations influence product strategy and deployment
Segmentation analysis reveals the nuanced contours of product development and clinical deployment across the membrane oxygenator spectrum. Devices differentiated by type show distinct engineering trade-offs: flat sheet designs prioritize predictable surface area exposure and simplified manufacturing workflows, whereas hollow fiber configurations deliver higher surface-to-volume ratios and scalability advantages for intensive oxygenation demands. Application-driven segmentation further increases granularity; blood oxygenation use in research encompasses both animal studies and in vitro studies, each with differing validation and sterility requirements, while cardiopulmonary bypass applications focus on procedures such as coronary artery bypass grafting and valve replacement surgery where priming volume and hemodynamic compatibility are critical. Extracorporeal membrane oxygenation applications bifurcate into venoarterial and venovenous configurations, each aligned to unique hemodynamic and oxygenation goals and to differing clinical protocols and monitoring needs.
End-user perspectives shape commercialization strategies with ambulatory surgical centers, hospitals, and research institutes exerting different procurement preferences, inventory turnover rates, and training expectations. Material segmentation underscores how polymethylpentene, polypropylene, and polysulfone present divergent balances of gas permeability, thermal stability, and manufacturability that influence choice for single-use versus reusable formats. Flow configuration-closed versus open-affects risk profiles, system integration complexity, and maintenance practices, while temperature segmentation into hypothermic and normothermic applications determines design emphases for thermal management and metabolic support. Understanding these interrelated segmentation dimensions enables stakeholders to tailor product design, clinical evidence generation, and go-to-market strategies to the precise use cases that drive adoption and clinical outcomes.
Regional strategic imperatives across the Americas Europe Middle East & Africa and Asia-Pacific that determine adoption regulatory approach and market entry dynamics
Regional dynamics create differentiated strategic priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific, shaping how manufacturers invest in distribution, regulatory affairs, and localized clinical partnerships. In the Americas, procurement tends to emphasize integrated service offerings, rapid logistical support, and alignment with established clinical guidelines, driving demand for devices with strong post-market surveillance and robust training programs. Europe, the Middle East & Africa presents heterogeneous regulatory regimes and variable hospital purchasing models, prompting suppliers to adopt flexible compliance strategies and to cultivate regional clinical champions who can support iterative device evaluation in diverse care settings.
Asia-Pacific is characterized by rapid growth in healthcare infrastructure investment and an expanding pool of local manufacturing capabilities, creating both opportunities for collaboration and competitive pressure from regional producers. Across regions, differences in standard clinical protocols, reimbursement mechanisms, and health system capacity influence device acceptance cycles and the types of clinical evidence that carry the most weight. Manufacturers that align regulatory submissions, localized clinical data packages, and after-sales support with these regional nuances will find greater success in market entry and sustained adoption, while those that adopt a one-size-fits-all approach risk slower uptake and constrained market access.
Market competitive landscape characterized by incumbents refining portfolios new entrants targeting niche applications and strategic moves toward vertical integration and service differentiation
Competitive dynamics in membrane oxygenators are shaped by incumbent leaders focusing on incremental product refinement and by emerging innovators pursuing material science breakthroughs and cost-efficient manufacturing models. Market participants are concentrating on differentiated value propositions that emphasize device reliability, minimized priming volumes, and compatibility with evolving extracorporeal circuit ecosystems. Strategic behaviors observed include vertical integration to capture more of the supply chain, partnerships with clinical centers for real-world evidence generation, and licensing arrangements for proprietary membrane technologies to accelerate time-to-market.
There is also a discernible shift toward service-oriented commercial models in which device sales are paired with training, implementation support, and data analytics that demonstrate clinical and operational impact. New entrants tend to target niche clinical indications or laboratory research applications where regulatory pathways and competitive barriers may be lower, using targeted clinical collaborations to build credibility. For established firms, the priority lies in defending clinical relationships, optimizing product portfolios to cover both acute care and research segments, and leveraging scale to invest in advanced materials and manufacturing automation that reduce per-unit variability and enhance product consistency.
Actionable strategic priorities for manufacturers and health system leaders to enhance supply resilience adoption and clinical value realization
Industry leaders should pursue a set of pragmatic actions to strengthen resilience and accelerate value delivery across clinical and commercial channels. First, diversifying material sourcing and qualifying alternate suppliers will reduce vulnerability to tariff shocks and supply interruptions while enabling comparative testing to identify cost-performance sweet spots. Second, investing in polymethylpentene and other high-performance polymers where clinically justified can yield improved device longevity and reduced complication rates, but this should be accompanied by rigorous clinical validation to support procurement decisions. Third, prioritizing modular product architectures and compatibility with standard extracorporeal circuit interfaces will lower barriers to adoption in varied clinical settings and make training more efficient.
Leaders should also expand partnerships with hospitals and research institutes to co-develop evidence that demonstrates operational benefits beyond unit price-such as reduced procedure time, lower transfusion requirements, or improved patient throughput. Strengthening regional regulatory and reimbursement intelligence teams will accelerate approvals and support nuanced market access strategies. Finally, implementing flexible commercial models that combine device supply with training services and outcome-based pilots will help align incentives with purchasers and establish long-term relationships that withstand pricing pressures and evolving tariff environments.
A mixed-methods research framework combining clinician interviews materials expertise laboratory validation and regulatory analysis to ensure robust evidence and actionable conclusions
This research applied a mixed-methods approach combining primary qualitative engagements and secondary technical synthesis to build a rigorous evidence base. Primary inputs included structured interviews with clinicians, perfusionists, and procurement professionals to capture real-world device performance considerations and adoption barriers. Supplementary consultations with manufacturing and materials experts provided insights into production constraints, polymer characteristics, and scaling challenges. Secondary analysis encompassed peer-reviewed literature, regulatory documentation, and technical standards that govern membrane device biocompatibility and sterilization, enabling triangulation of clinical priorities with engineering constraints.
Data validation steps included cross-referencing interview findings with laboratory performance data and publicly available regulatory filings to ensure consistency in reported device attributes and claimed benefits. The methodology emphasized segmentation mapping to align device characteristics with application-specific requirements and end-user needs. Quality assurance processes involved iterative review cycles with domain experts and reconciliation of divergent inputs to form balanced conclusions. The combined approach ensured that strategic implications are grounded in both clinical practice and manufacturability considerations while maintaining transparency about assumptions and evidence sources.
Concluding synthesis on how technology clinical evidence and supply resilience converge to determine future adoption performance and market positioning
In summary, membrane oxygenators remain a focal point of clinical innovation and operational emphasis within cardiovascular and critical care pathways, driven by advances in materials, growing clinical reliance on extracorporeal support modalities, and evolving procurement dynamics. The interplay between device form factors, application-specific requirements, and regional healthcare system characteristics necessitates nuanced strategies that prioritize clinical evidence, supply resilience, and adaptable product design. Trade-related developments and shifting geopolitical dynamics add urgency to supplier diversification and local manufacturing considerations, while regulatory expectations continue to elevate the importance of rigorous post-market surveillance.
For stakeholders, the path forward involves aligning R&D investments with demonstrable clinical outcomes, tailoring market access approaches to regional idiosyncrasies, and adopting commercial models that link device adoption to measurable operational benefits. Organizations that execute on these imperatives will be better positioned to serve clinicians and patients effectively, sustain competitive advantage, and respond to emerging disruptions with agility and confidence.
Note: PDF & Excel + Online Access - 1 Year
A concise overview of membrane oxygenator relevance across clinical, research and perfusion applications emphasizing technological and clinical drivers
Membrane oxygenators sit at the intersection of critical-care innovation and biomedical engineering, serving as indispensable components in extracorporeal life support and perfusion systems. Over the past decade, clinicians and researchers have relied on advances in membrane design and polymer science to sustain complex cardiopulmonary procedures and to enable prolonged extracorporeal support in acute respiratory and cardiac failure. The technology’s utility spans controlled laboratory environments and high-acuity clinical settings, where device performance directly influences patient outcomes.
This introduction frames the current landscape by emphasizing converging drivers: evolving clinical demand patterns, material and manufacturing breakthroughs, and heightened regulatory scrutiny around biocompatibility and sterility. The narrative draws attention to distinctions in form factors and configurations that influence clinical adoption, and it underscores the interplay between device architecture and procedural applications. By situating membrane oxygenators within wider healthcare delivery trends-such as increasing emphasis on minimally invasive procedures and expanding use of extracorporeal support-this section sets the context for deeper analysis of market dynamics, technological inflection points, and strategic considerations for manufacturers and healthcare purchasers alike.
How material breakthroughs clinical practice evolution and supply resiliency initiatives are reshaping product design adoption and competitive positioning
The landscape for membrane oxygenators is undergoing a sequence of transformative shifts driven by material innovation, clinical practice changes, and supply chain realignment. Recent progress in polymer science, particularly the broader adoption of advanced hollow fiber membranes and next-generation polymethylpentene materials, has improved gas exchange efficiency and reduced plasma leakage, prompting device redesigns and reconsideration of perfusion protocols. Concurrently, clinical pathways have shifted toward more frequent and earlier deployment of extracorporeal support in severe respiratory failure, which in turn has elevated expectations for device endurance, ease of priming, and integration with monitoring platforms.
Manufacturers are responding by modularizing product families and prioritizing single-use disposables that balance infection control with operational efficiency. At the same time, intensified regulatory attention on biocompatibility, sterilization validation, and real-world performance data is reshaping R&D priorities and clinical evidence generation. Digital tooling and simulation are being applied to accelerate development cycles and to optimize flow configurations for specific surgical and extracorporeal use cases. As stakeholders adapt, strategic emphasis is shifting from incremental improvements to systemic rethinking of supply resiliency, clinical training, and lifecycle cost management, creating new opportunities for differentiated product positioning and collaborative clinical research.
Strategic consequences of 2025 United States tariff actions on sourcing manufacturing partnerships pricing models and procurement resilience
United States tariff measures announced in 2025 have introduced a new layer of strategic complexity for manufacturers and purchasers of membrane oxygenators, prompting operational adjustments across sourcing, pricing, and distribution networks. The tariffs have encouraged organizations to re-evaluate global procurement footprints and to accelerate consideration of nearshoring or local manufacturing partnerships as a means to insulate operations from trade-related cost volatility. Procurement teams have increasingly prioritized supplier diversification and long-term contracts with clauses that mitigate exposure to tariff fluctuations, while product teams are reassessing the total cost implications of material choices and component sourcing.
Regulatory and reimbursement environments have also been indirectly affected, as hospitals and purchasing coalitions seek transparent cost justifications for capital and disposable device selections. In response, suppliers have intensified efforts to demonstrate value through clinical evidence, reduced operating times, and lower complication rates rather than relying solely on purchase price. The tariffs have further incentivized innovation in material efficiency and manufacturing automation to offset added customs-related expenses. Ultimately, organizations that proactively adapt pricing models, secure resilient supplier arrangements, and provide clear clinical and economic value narratives are positioned to navigate the tariff environment with less disruption to patient care and supply continuity.
Deep segmentation-driven insights revealing how type application end-user material flow configuration and temperature considerations influence product strategy and deployment
Segmentation analysis reveals the nuanced contours of product development and clinical deployment across the membrane oxygenator spectrum. Devices differentiated by type show distinct engineering trade-offs: flat sheet designs prioritize predictable surface area exposure and simplified manufacturing workflows, whereas hollow fiber configurations deliver higher surface-to-volume ratios and scalability advantages for intensive oxygenation demands. Application-driven segmentation further increases granularity; blood oxygenation use in research encompasses both animal studies and in vitro studies, each with differing validation and sterility requirements, while cardiopulmonary bypass applications focus on procedures such as coronary artery bypass grafting and valve replacement surgery where priming volume and hemodynamic compatibility are critical. Extracorporeal membrane oxygenation applications bifurcate into venoarterial and venovenous configurations, each aligned to unique hemodynamic and oxygenation goals and to differing clinical protocols and monitoring needs.
End-user perspectives shape commercialization strategies with ambulatory surgical centers, hospitals, and research institutes exerting different procurement preferences, inventory turnover rates, and training expectations. Material segmentation underscores how polymethylpentene, polypropylene, and polysulfone present divergent balances of gas permeability, thermal stability, and manufacturability that influence choice for single-use versus reusable formats. Flow configuration-closed versus open-affects risk profiles, system integration complexity, and maintenance practices, while temperature segmentation into hypothermic and normothermic applications determines design emphases for thermal management and metabolic support. Understanding these interrelated segmentation dimensions enables stakeholders to tailor product design, clinical evidence generation, and go-to-market strategies to the precise use cases that drive adoption and clinical outcomes.
Regional strategic imperatives across the Americas Europe Middle East & Africa and Asia-Pacific that determine adoption regulatory approach and market entry dynamics
Regional dynamics create differentiated strategic priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific, shaping how manufacturers invest in distribution, regulatory affairs, and localized clinical partnerships. In the Americas, procurement tends to emphasize integrated service offerings, rapid logistical support, and alignment with established clinical guidelines, driving demand for devices with strong post-market surveillance and robust training programs. Europe, the Middle East & Africa presents heterogeneous regulatory regimes and variable hospital purchasing models, prompting suppliers to adopt flexible compliance strategies and to cultivate regional clinical champions who can support iterative device evaluation in diverse care settings.
Asia-Pacific is characterized by rapid growth in healthcare infrastructure investment and an expanding pool of local manufacturing capabilities, creating both opportunities for collaboration and competitive pressure from regional producers. Across regions, differences in standard clinical protocols, reimbursement mechanisms, and health system capacity influence device acceptance cycles and the types of clinical evidence that carry the most weight. Manufacturers that align regulatory submissions, localized clinical data packages, and after-sales support with these regional nuances will find greater success in market entry and sustained adoption, while those that adopt a one-size-fits-all approach risk slower uptake and constrained market access.
Market competitive landscape characterized by incumbents refining portfolios new entrants targeting niche applications and strategic moves toward vertical integration and service differentiation
Competitive dynamics in membrane oxygenators are shaped by incumbent leaders focusing on incremental product refinement and by emerging innovators pursuing material science breakthroughs and cost-efficient manufacturing models. Market participants are concentrating on differentiated value propositions that emphasize device reliability, minimized priming volumes, and compatibility with evolving extracorporeal circuit ecosystems. Strategic behaviors observed include vertical integration to capture more of the supply chain, partnerships with clinical centers for real-world evidence generation, and licensing arrangements for proprietary membrane technologies to accelerate time-to-market.
There is also a discernible shift toward service-oriented commercial models in which device sales are paired with training, implementation support, and data analytics that demonstrate clinical and operational impact. New entrants tend to target niche clinical indications or laboratory research applications where regulatory pathways and competitive barriers may be lower, using targeted clinical collaborations to build credibility. For established firms, the priority lies in defending clinical relationships, optimizing product portfolios to cover both acute care and research segments, and leveraging scale to invest in advanced materials and manufacturing automation that reduce per-unit variability and enhance product consistency.
Actionable strategic priorities for manufacturers and health system leaders to enhance supply resilience adoption and clinical value realization
Industry leaders should pursue a set of pragmatic actions to strengthen resilience and accelerate value delivery across clinical and commercial channels. First, diversifying material sourcing and qualifying alternate suppliers will reduce vulnerability to tariff shocks and supply interruptions while enabling comparative testing to identify cost-performance sweet spots. Second, investing in polymethylpentene and other high-performance polymers where clinically justified can yield improved device longevity and reduced complication rates, but this should be accompanied by rigorous clinical validation to support procurement decisions. Third, prioritizing modular product architectures and compatibility with standard extracorporeal circuit interfaces will lower barriers to adoption in varied clinical settings and make training more efficient.
Leaders should also expand partnerships with hospitals and research institutes to co-develop evidence that demonstrates operational benefits beyond unit price-such as reduced procedure time, lower transfusion requirements, or improved patient throughput. Strengthening regional regulatory and reimbursement intelligence teams will accelerate approvals and support nuanced market access strategies. Finally, implementing flexible commercial models that combine device supply with training services and outcome-based pilots will help align incentives with purchasers and establish long-term relationships that withstand pricing pressures and evolving tariff environments.
A mixed-methods research framework combining clinician interviews materials expertise laboratory validation and regulatory analysis to ensure robust evidence and actionable conclusions
This research applied a mixed-methods approach combining primary qualitative engagements and secondary technical synthesis to build a rigorous evidence base. Primary inputs included structured interviews with clinicians, perfusionists, and procurement professionals to capture real-world device performance considerations and adoption barriers. Supplementary consultations with manufacturing and materials experts provided insights into production constraints, polymer characteristics, and scaling challenges. Secondary analysis encompassed peer-reviewed literature, regulatory documentation, and technical standards that govern membrane device biocompatibility and sterilization, enabling triangulation of clinical priorities with engineering constraints.
Data validation steps included cross-referencing interview findings with laboratory performance data and publicly available regulatory filings to ensure consistency in reported device attributes and claimed benefits. The methodology emphasized segmentation mapping to align device characteristics with application-specific requirements and end-user needs. Quality assurance processes involved iterative review cycles with domain experts and reconciliation of divergent inputs to form balanced conclusions. The combined approach ensured that strategic implications are grounded in both clinical practice and manufacturability considerations while maintaining transparency about assumptions and evidence sources.
Concluding synthesis on how technology clinical evidence and supply resilience converge to determine future adoption performance and market positioning
In summary, membrane oxygenators remain a focal point of clinical innovation and operational emphasis within cardiovascular and critical care pathways, driven by advances in materials, growing clinical reliance on extracorporeal support modalities, and evolving procurement dynamics. The interplay between device form factors, application-specific requirements, and regional healthcare system characteristics necessitates nuanced strategies that prioritize clinical evidence, supply resilience, and adaptable product design. Trade-related developments and shifting geopolitical dynamics add urgency to supplier diversification and local manufacturing considerations, while regulatory expectations continue to elevate the importance of rigorous post-market surveillance.
For stakeholders, the path forward involves aligning R&D investments with demonstrable clinical outcomes, tailoring market access approaches to regional idiosyncrasies, and adopting commercial models that link device adoption to measurable operational benefits. Organizations that execute on these imperatives will be better positioned to serve clinicians and patients effectively, sustain competitive advantage, and respond to emerging disruptions with agility and confidence.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
199 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Development of bioactive heparin-bonded polymer membranes to reduce clotting risk in extracorporeal life support
- 5.2. Integration of real-time sensor arrays and AI-driven analytics for predictive membrane performance monitoring
- 5.3. Miniaturization of portable extracorporeal membrane oxygenators for in-field emergency applications
- 5.4. Advancements in polymethylpentene membrane manufacturing using 3D printing for customized flow dynamics
- 5.5. Regulatory alignment for extended duration ECMO devices supporting multi-week patient therapies
- 5.6. Emergence of pediatric-specific low-prime oxygenator designs to minimize hemodilution in neonatal care
- 5.7. Implementation of heparin-free surface coatings utilizing nitric oxide-releasing polymers to enhance biocompatibility
- 5.8. Escalating adoption of membrane oxygenators in ECMO for severe respiratory failure and post-cardiac surgery support in high-acuity ICUs
- 5.9. Shift toward hollow fiber and polymethylpentene membrane oxygenators delivering higher gas transfer efficiency and longer functional lifespan
- 5.10. Rapid expansion of ECMO-capable centers in Asia Pacific driving localized manufacturing and cost-optimized membrane oxygenator platforms
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Membrane Oxygenators Market, by Product Type
- 8.1. Cardiopulmonary Bypass Oxygenators
- 8.1.1. Adult Cardiopulmonary Oxygenators
- 8.1.2. Pediatric Cardiopulmonary Oxygenators
- 8.1.3. Neonatal Cardiopulmonary Oxygenators
- 8.2. Extracorporeal Life Support Oxygenators
- 8.2.1. Veno-Arterial ECMO Oxygenators
- 8.2.2. Veno-Venous ECMO Oxygenators
- 8.2.3. Hybrid / Configurable ECMO Oxygenators
- 8.3. Integrated Oxygenator-Heat Exchangers
- 8.4. Standalone Oxygenators (Without Heat Exchanger)
- 9. Membrane Oxygenators Market, by Material
- 9.1. Polymethylpentene
- 9.2. Polypropylene
- 9.3. Polysulfone
- 10. Membrane Oxygenators Market, by Flow Configuration
- 10.1. Closed
- 10.2. Open
- 11. Membrane Oxygenators Market, by Temperature
- 11.1. Hypothermic
- 11.2. Normothermic
- 12. Membrane Oxygenators Market, by Application
- 12.1. Blood Oxygenation For Research
- 12.1.1. Animal Studies
- 12.1.2. In Vitro Studies
- 12.2. Cardiopulmonary Bypass
- 12.2.1. Coronary Artery Bypass Grafting
- 12.2.2. Valve Replacement Surgery
- 12.3. Extracorporeal Membrane Oxygenation
- 12.3.1. Venoarterial ECMO
- 12.3.2. Venovenous ECMO
- 13. Membrane Oxygenators Market, by End User
- 13.1. Ambulatory Surgical Centers
- 13.2. Hospitals & Research Institutes
- 14. Membrane Oxygenators Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Membrane Oxygenators Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Membrane Oxygenators Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. Getinge AB
- 17.3.2. Medtronic PLC
- 17.3.3. LivaNova PLC
- 17.3.4. Terumo Corporation
- 17.3.5. Fresenius Medical Care AG & Co. KGaA
- 17.3.6. Merck KGaA
- 17.3.7. Nipro Corporation
- 17.3.8. Asahi Kasei Medical Co., Ltd.
- 17.3.9. Xenios AG
- 17.3.10. Nikkiso Co., Ltd.
- 17.3.11. MicroPort Scientific Corporation
- 17.3.12. Dongguan Kewei Medical Instrument Co., Ltd.
- 17.3.13. EUROSETS S.r.l.
- 17.3.14. Shandong Weigao Group Medical Polymer Company Limited
- 17.3.15. BRAILE BIOMEDICA INDUSTRIA COMERCIO E REPRESENTACOES LTDA
- 17.3.16. Senko Medical Instrument Mfg. Co., Ltd.
- 17.3.17. Chalice Medical Ltd
- 17.3.18. Abbott Laboratories
- 17.3.19. CytoSorbents Corporation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
